Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

The names on this page are hidden. Create a free account and they fill in. No card, and every figure, date and source on this page is public either way.

Companies / 3•••••••

3•••••••

Series CUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$53.0Msum of rounds with a disclosed amount only
Named investors
4
Financing history
1 rounds
  1. Nov 26, 2024
    Series C · $53.0M (disclosed)
    F•••••• L••• S••••••• (lead)D••• T•••• C•••••• (participant)P••••••• B••••••••• A••••••• (participant)C••••••• T••••••••• (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “3••••••• Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity”
Investors on record
4 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Nov 26, 2024
    3••••••• announced Series C of $53,000,000, led by F•••••• L••• S•••••••
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company